NASDAQ:PRVB

Provention Bio Stock Forecast, Price & News

$14.86

-0.13 (-0.87 %)

(As of 01/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$14.41

Now: $14.86▼

$15.40

50-Day Range

$14.99

MA: $17.20▼

$19.45

52-Week Range

$4.72

Now: $14.86▼

$20.05

Volume1.31 million shs

Average Volume1.56 million shs

Market Capitalization$839.41 million

P/E RatioN/A

Dividend YieldN/A

Beta3.34

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.

Overall MarketRank^™

1.39 out of 5 stars

Medical Sector

560th out of 1,928 stocks

Pharmaceutical Preparations Industry

281st out of 774 stocks

3.5 Analyst's Opinion

Consensus Rating
Provention Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.00, Provention Bio has a forecasted upside of 95.2% from its current price of $14.86.
Amount of Analyst Coverage
Provention Bio has only been the subject of 1 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Provention Bio has received 146 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Provention Bio has received 133 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Provention Bio has received 52.33% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Provention Bio and other stocks. Vote “Outperform” if you believe PRVB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRVB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Provention Bio does not currently pay a dividend.
Dividend Growth
Provention Bio does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Provention Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 14.40% of the stock of Provention Bio is held by insiders.
Percentage Held by Institutions
39.42% of the stock of Provention Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Provention Bio are expected to decrease in the coming year, from ($1.77) to ($1.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Provention Bio is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Provention Bio is -9.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Provention Bio has a P/B Ratio of 8.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PRVB

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.proventionbio.com

Phone908-336-0360

Employees19

Debt

Debt-to-Equity RatioN/A

Current Ratio9.23

Quick Ratio9.23

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.72 per share

Price / Book8.64

Profitability

EPS (Most Recent Fiscal Year)($1.06)

Net Income$-43,280,000.00

Net MarginsN/A

Return on Equity-67.66%

Return on Assets-62.27%

Miscellaneous

Outstanding Shares56,488,000

Market Cap$839.41 million

Next Earnings Date3/11/2021 (Estimated)

OptionableNot Optionable

$14.86

-0.13 (-0.87 %)

(As of 01/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PRVB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRVB and its competitors with MarketBeat's FREE daily newsletter.

Provention Bio (NASDAQ:PRVB) Frequently Asked Questions

How has Provention Bio's stock price been impacted by COVID-19 (Coronavirus)?

Provention Bio's stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PRVB shares have increased by 64.9% and is now trading at $14.86.
View which stocks have been most impacted by COVID-19.

Is Provention Bio a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Provention Bio stock.
View analyst ratings for Provention Bio or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Provention Bio?

Wall Street analysts have given Provention Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Provention Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Provention Bio's CEO?

1,428 employees have rated Provention Bio CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Provention Bio's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Provention Bio's next earnings date?

Provention Bio is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Provention Bio.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) posted its quarterly earnings results on Thursday, November, 5th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.16.
View Provention Bio's earnings history.

What price target have analysts set for PRVB?

5 Wall Street analysts have issued 1-year price objectives for Provention Bio's stock. Their forecasts range from $25.00 to $40.00. On average, they anticipate Provention Bio's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 95.2% from the stock's current price.
View analysts' price targets for Provention Bio or view Wall Street analyst' top-rated stocks.

Who are some of Provention Bio's key competitors?

Some companies that are related to Provention Bio include Corcept Therapeutics (CORT), Prelude Therapeutics (PRLD), Pacira BioSciences (PCRX), Agios Pharmaceuticals (AGIO), CytoDyn (CYDY), ALX Oncology (ALXO), IGM Biosciences (IGMS), Nektar Therapeutics (NKTR), OPKO Health (OPK), Global Blood Therapeutics (GBT), I-Mab (IMAB), Rocket Pharmaceuticals (RCKT), Taro Pharmaceutical Industries (TARO), Xencor (XNCR) and Deciphera Pharmaceuticals (DCPH).
View all of PRVB's competitors.

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

Who are Provention Bio's key executives?

Provention Bio's management team includes the following people:

Mr. Ashleigh W. Palmer B.Sc., M.B.A., Co-Founder, Pres, CEO & Director (Age 57, Pay $651.2k)
Mr. Francisco Leon M.D., Ph.D., Co-Founder & Chief Scientific Officer (Age 48, Pay $538.2k)
Mr. Andrew T. Drechsler, Chief Financial Officer (Age 48, Pay $510.4k)
Dr. Eleanor L. Ramos, Chief Medical Officer (Age 64, Pay $580.7k)
Ms. Heidy Abreu King-Jones J.D., L.L.M., Chief Legal Officer (Age 37)
Dr. Sherron Kell, Sr. VP of Clinical Devel.
Mr. Jason Hoitt, Chief Commercial Officer (Age 42)

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Liberty One Investment Management LLC (0.01%). Company insiders that own Provention Bio stock include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Eleanor Ramos, Francisco Leon and Jason Hoitt.
View institutional ownership trends for Provention Bio.

Which major investors are buying Provention Bio stock?

PRVB stock was purchased by a variety of institutional investors in the last quarter, including Liberty One Investment Management LLC. Company insiders that have bought Provention Bio stock in the last two years include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, and Jason Hoitt.
View insider buying and selling activity for Provention Bio or or view top insider-buying stocks.

How do I buy shares of Provention Bio?

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $14.86.

How big of a company is Provention Bio?

Provention Bio has a market capitalization of $839.41 million. The company earns $-43,280,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Provention Bio employs 19 workers across the globe.

What is Provention Bio's official website?

The official website for Provention Bio is www.proventionbio.com.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at 908-336-0360 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here